Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Fu, 2020
 
ChiCTR2000030262
RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 no results
    Khamis, 2020 RCTinterferonstandard of careCOVID-19 mild to moderatesome concern
    44/45 inconclusive

      COVID-19 severe or critically meta-analysis

      Davoudi-Monfared, 2020
       
      IRCT20100228003449N2
      RCTinterferonstandard of careCOVID-19 severe or criticallyhigh
      46/46 no results
        Yekaninejad, 2020
         
        IRCT20100228003449N2
        RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
        33/33 conclusif
        • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).